Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Generex Granted China Patent for Cancer Vaccine

publication date: Mar 3, 2010
Generex Biotechnology announced it has been granted a China patent for its Ii-Key peptide vaccine technology, a vaccine currently in US clinical trials to prevent a recurrence of breast cancer. Generex said the patent covers both its platform technologies and Ii-Key-containing drug development compounds. Generex is “actively seeking” either joint venture or licensing partnerships for the vaccine, and it has already begun discussions with several large pharmas. More details...

Stock Symbol: (NSDQ: GNBT)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital